| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11017185 | American Heart Journal | 2018 | 44 Pages |
Abstract
The results from the VERTIS-CV trial will define the CV and renal safety and efficacy of ertugliflozin in patients with T2DM and ASCVD.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Christopher P. MD, Darren K. MD, MHSc, Richard MD, Sam MD, James PhD, Susan DrPH, Bernard MD, Weichung J. PhD, Silvina MD, Urszula MD, Gregory PhD, Francesco MD, PhD, Brett MD, PhD, Steven G. PharmD, VERTIS-CV Investigators VERTIS-CV Investigators,